Evidence map›Paper›PMID 41662324›Full record

ReviewCardiorenal medicine2026

Ten Hot Topics in Cardiovascular Risk Management for Chronic Kidney Disease.

María Marques, Alberto Ortiz, Gregorio Romero-González, Javier Díez, Rafael Santamaría, Adriana Puente-García, Roberto Alcázar, Patricia de Sequera, José Luis Górriz, Borja Quiroga

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

María MarquesNephrology Department, Hospital Universitario Puerta de Hierro-Majadahonda IDIPHISA, Madrid, Spain.
Alberto OrtizRICORS 2040-Renal, Madrid, Spain.
Gregorio Romero-GonzálezNephrology Department, University Hospital Germans Trias i Pujol (HGiTP) & REMAR-IGTP Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Medicine Department, Universitat Autònoma de Barcelona, Badalona, Spain, iatros36@icloud.com.
Javier DíezCenter for Applied Medical Research (CIMA), and School of Medicine, University of Navarra, Pamplona, Spain.
Rafael SantamaríaNephrology Department, Reina Sofia University Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Córdoba, Spain.
Adriana Puente-GarcíaNephrology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Roberto AlcázarNephrology Department, Hospital Universitario Infanta Leonor, Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Patricia de SequeraRICORS 2040-Renal, Madrid, Spain.
José Luis GórrizRICORS 2040-Renal, Madrid, Spain.
Borja QuirogaRICORS 2040-Renal, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with a markedly increased risk of cardiovascular disease (CVD). Despite this, cardiovascular risk in patients with CKD is frequently underestimated and insufficiently treated in routine clinical practice. SUMMARY: In this narrative review, we address ten concise and up-to-date questions focused on cardiovascular risk management in CKD. A panel of ten expert nephrologists provides evidence-based perspectives on key aspects including assessment of the arterial tree, cardiovascular risk estimation, identification of biomarkers for improved risk stratification, and both pharmacological and non-pharmacological interventions proven to reduce cardiovascular risk. Additional topics include blood pressure targets, optimal management of dyslipidemia, and cardiovascular risk management in patients receiving renal replacement therapy. Practical strategies to translate this evidence into everyday clinical care are also discussed. KEY MESSAGE: A comprehensive and structured approach to cardiovascular risk assessment and management are essential in patients with CKD and should be systematically integrated into routine nephrology practice to improve cardiovascular outcomes.

Indexed as

Cardiovascular DiseasesRenal Insufficiency, ChronicRisk ManagementDyslipidemiasHeart Disease Risk FactorsHumansRisk AssessmentRisk FactorsCardiovascular riskChronic kidney diseaseVascular event

Identifiers

PMID41662324
PMCPMC13046305

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.